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Natriuretic peptides have been proposed as biomarkers of cardiovascular disease, espe-
cially heart failure. Brain natriuretic peptide (BNP) has also been shown to be upregulated at
the transcriptional and translational levels by pro-inflammatory cytokines in cardiac myo-
cytes. Although we often measure plasma BNP levels in cancer patients, it remains
unknown whether cancer-related inflammation affects the plasma BNP levels. We investi-
gated the relationship between the BNP and human cancers.
Methods
We retrospectively studied 2,923 patients in whom the plasma BNP levels and serum C-
reactive protein (CRP) were measured and echocardiography was performed. Patients with
clinically evident heart failure (NYHA II or higher), heart disease requiring medical treatment
or surgery, renal dysfunction, and inflammatory disease were excluded. There were 234
patients in the final analysis. Blood sampling was performed before surgery and chemother-
apy. In addition, we evaluated the relationship between the inflammation and plasma BNP
levels in mouse models of colon cancer.
Results
Of the 234 patients, 80 were diagnosed with cancer. Both the plasma BNP and serum CRP
levels were significantly higher in cancer patients than those without. There were no signifi-
cant differences in the echocardiographic parameters. There was a significant positive cor-
relation between the plasma BNP and serum CRP levels in cancer patients (r = 0.360,
P<0.01) but not in those without. In cancer patients, only the CRP correlated with the BNP
independent of the age, creatinine level, hypertension, and body mass index. In addition, in
nude mice with subcutaneous colon cancer, the plasma BNP level was elevated compared
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with that in non-cancer mice, and there was a significant relationship between the plasma
BNP and serum levels of the inflammatory markers.
Conclusions
In cancer patients, as well as colon cancer model mice, the plasma BNP levels were ele-
vated, possibly due to cancer-related inflammation. The effect of cancer on the BNP levels
should be considered when using BNP as an indicator of heart failure in cancer patients.
Introduction
The family of natriuretic peptides plays an important role in the regulation of cardiovascular
homeostasis and extracellular fluid volume. The natriuretic peptide system consists of at least
three structurally homologous peptides, including atrial natriuretic peptide (ANP), brain
natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) [1,2]. ANP is synthesized pri-
marily by the atrial myocardium, whereas BNP is synthesized mainly by the ventricular myo-
cardium in response to a volume overload and increased wall tension [3]. Several lines of
evidence suggest that BNP is superior to the other cardiac biomarkers including ANP for the
prognostication and risk stratification in patients with heart failure [4–6]. Therefore, BNP and
N-terminal (NT)-proBNP have been used as biomarkers for the diagnosis, guiding therapy,
and prognostication, and have been studied in clinical trials and studies [7].
Recently, natriuretic peptides have been reported to reduce the number of small cell and
squamous cell lung cancer cells and inhibit progression of several cancers, such as pancreatic
cancer, breast cancer, small cell lung cancer, and prostate adenocarcinomas, in vivo and in
vitro [8]. The underlying mechanism is hypothesized to be the inhibition of the mitogen acti-
vated extracellular signal-regulated kinases (ERK) 1/2 and DNA synthesis, mediated in part by
cyclic GMP [9]. In addition, endogenous ANP has been shown to be expressed in the nucleus
and cytoplasm of the human pancreatic adenocarcinomas [10]. ANP is also localized to the
endothelium of capillaries and fibroblasts within these tumors [10].
On the other hand, inflammatory conditions are usually present before a malignant change
occurs, and an oncogenic change generates an inflammatory microenvironment that promotes
the development of tumors [11]. BNP has been shown to be upregulated at the transcriptional
and translational levels by pro-inflammatory cytokines in cardiac myocytes [12]. Thus, we
hypothesized that the natriuretic peptide levels are increased in cancer patients as a response
to cancer-related inflammation. BNP has been measured in many patients with cancer to rule
out heart disease in our hospital. Therefore, in the present study, we retrospectively investi-
gated the relationship between the BNP concentrations and human cancers. In addition, to
confirm the hypothesis, we evaluated the relationship between the inflammation and plasma
BNP levels in nude mice with subcutaneous colon cancer.
Materials and methods
Patient characteristics
We retrospectively studied 2,923 patients in whom the plasma BNP, serum C-reactive protein
(CRP), and creatinine levels were measured and echocardiography was performed in our hos-
pital. Patients with clinically evident heart failure (NYHA II or higher), heart disease requiring
medical treatment or surgery, severe renal dysfunction (defined as a GFR 30 mL/min/1.73
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m2), and inflammatory disease were excluded. Patients with cancer after treatments such as
surgery, chemotherapy, or radiation, were also excluded. We included 234 patients in the final
analysis. The study protocol was approved by the Institutional Review Board of Tokushima
University Hospital. The patient records were anonymized and de-identified prior to the
analysis.
Eighty patients were diagnosed with cancer. In 71 cancer patients without leukemia or a
multiple myeloma or primary macroglobulinemia, the tumor staging was based on the TNM
classification system of the American Joint Committee on Cancer staging criteria.
Laboratory data
Blood sampling was performed within two weeks before the surgery or chemotherapy. We
examined the plasma BNP, serum CRP, and serum creatinine levels when the patients had
symptoms suggestive of heart failure. In addition, we also examined the plasma BNP levels in
the same patients who could be followed up after surgery or a full course of chemotherapy (48
out of 80 patients with cancer). In these patients, the blood sampling was performed at least 1
month after the completion of the surgery or chemotherapy to exclude any effect of the surgery
or chemotherapy. The sample for the BNP assay was transferred into tubes containing 1.5 mg/
mL of 2Na-EDTA. Immediately after a rapid centrifugation at 3,000 rpm for 5 minutes, the
plasma BNP concentration was determined using a commercially available immuno enzymo-
metric assay (ST E test “TOSOH” II BNP; Tosoh, Tokyo, Japan). In addition, we also examined
the plasma BNP levels in the same patients who could be followed up after the surgery or a full
course of chemotherapy.
Echocardiography
Transthoracic echocardiography was performed in all 234 patients before the surgery or che-
motherapy. We used the echocardiographic data obtained one week before or after the BNP
measurement. The left ventricular ejection fraction (LVEF) was measured using a modified
Simpson’s biplane method. The left ventricular end-diastolic dimension (LVDd) was mea-
sured with M-mode in the parasternal long axis view. The left ventricular mass index (LVMI)
was calculated using Devereux’s formula with the diastolic measurements of the left ventricular
internal diameter (LVID), interventricular septal thickness (IVST), and posterior wall thick-
ness (PWT): LVMI (g/m2) = (1.04 [(IVST + LVID + PWT)3 − LVID3] − 14 g) / body surface
area. In addition, the motion of the mitral annulus was recorded in the apical four-chamber
view and a 4–5 mm sample volume was positioned sequentially at the lateral and septal corners
of the mitral annulus. The peak early (E´) and late (A´) diastolic mitral annular velocities were
determined, as well as the E/e´ (the mitral inflow E velocity to tissue Doppler e´ ratio).
Mouse models of colon cancer
Female BALB/cA nu/nu mice (age 5 weeks) were purchased from CLEA Japan, Inc. (Tokyo,
Japan) and maintained in the animal housing facility at Tokushima University Graduate
School. Subcutaneous tumors were induced by an injection of 107 LIM 1215 cells in the groin
at the age of 6–7 weeks. They were euthanized by cervical dislocation after the transthoracic
echocardiography (SonoScape S6V) and blood sampling were performed at 6 weeks when the
tumor size reached approximated 10 mm in diameter (maximum tumor size was 12mm).
Mice with the tumor size less than 7mm were excluded. Then, we examined the plasma BNP
and serum CRP levels, interleuin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α by an
enzyme-linked immunosorbent assay.
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The health status of all mice was monitored by a sentinel program throughout the experi-
ments. All mice were housed under a 12-hour light/dark cycle, with food and water available
ad libitum. All experimental procedures conformed to the guidelines for animal experimenta-
tion of Tokushima University.
Statistical analysis
Continuous variables are expressed as means ± standard deviation (SD). Categorical data are
presented as absolute values and percentages. With regard to the patient characteristics, labo-
ratory measurements, and echocardiographic parameters, comparisons between 2 groups
were performed using a Student’s t-test and comparisons among 4 groups were evaluated by a
one-way analysis of variance (ANOVA) followed by a Bonferroni correction. A multivariate
logistic regression analysis was performed to identify any clinical factors and laboratory
parameters associated with the plasma BNP levels. Differences were considered statistically sig-
nificant for a p<0.05.
Results
Patient characteristics
The baseline characteristics of the 234 patients included in the present study are shown in
Table 1. The study patients were divided into cancer (before the treatment) and non-cancer
groups. The cancer group included 80 patients (35%) and the non-cancer group consisted of
154 patients (65%). There were no significant differences in the age (Cancer (-): 67.9±13.7 vs.
Cancer (+): 72.4±11.9 years), male/female ratio (Cancer (-): 66/88 vs. Cancer (+): 33/47), creat-
inine level (Cancer (-): 0.85±0.36 vs. Cancer (+): 0.85±0.43 mg/dl), or body mass index (Can-
cer (-): 22.5±3.5 vs. Cancer (+): 22.1±3.9 kg/m2) between the two groups. The cancer group
(n = 80) consisted of 12 patients (15%) with malignant lymphomas, 8 patients (10%) with
colon cancer, 8 patients (10%) with prostate cancer, 7 patients (9%) with gastric cancer, 7
patients (9%) with breast cancer, 5 patients (7%) with lung cancer, 4 patients (5%) with liver
cancer, 4 patients (5%) with pancreatic cancer, and 25 patients (31%) with other types of can-
cer. The main clinical diagnosis or symptoms in the non-cancer group (n = 154) were hyper-
tension (n = 37), chest pain/dyspnea caused by non-cardiac diseases (n = 21), cerebrovascular
disease (n = 16), preoperative screening (n = 16), mild valvular heart disease that did not need
treatment (n = 11), diabetes mellitus (n = 10), arrhythmias that did not need treatment (n = 8),
respiratory disease (n = 7), dyslipidemia (n = 5), aortic aneurysm (n = 4), peripheral vascular
disease (n = 4), and others (n = 15).
BNP and CRP levels in patients with and without cancer
The plasma BNP levels were significantly higher in the patients with cancer than in those with-
out (66.4±56.3 vs. 44.0±35.3 pg/ml, p<0.01). The serum CRP levels were also significantly
Table 1. Patient characteristics.
Cancer (-) (n = 154) Cancer (+) (n = 80)
Age (years) 67.9±13.7 72.4±11.9
Male/Female 66/88 33/47
Creatinine (mg/dl) 0.85±0.36 0.85±0.43
Body mass index (kg/m2) 22.5±3.5 22.1±3.9
https://doi.org/10.1371/journal.pone.0178607.t001
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higher in the patients with cancer than in those without (0.99±1.56 vs. 0.18±0.27 mg/dl,
p<0.01) (Fig 1).
BNP levels in the patients with different stages of cancer
The plasma BNP levels were significantly higher in the patients with stage IV cancer than in
those with stage I, II, or III. There were no significant differences in the BNP levels between
the cancer patients with stages I, II, and III (Fig 2).
Echocardiographic parameters in the patients with and without cancer
The echocardiographic parameters of the LVEF (65.0±8.4 vs. 65.0±8.2%, p = 0.994), LVMI
(112.0±37.0 vs. 118.3±38.3 g/m2, p = 0.231), LVDd (4.58±0.61 vs. 4.73±0.66 cm, p = 0.108),
and E/e´ (9.4±3.9 vs. 10.1±3.7, p = 0.303) were similar in the patients with and without cancer.
There were no echocardiographic findings suggestive of heart failure in the 234 patients with
and without cancer.
Relationship between the plasma BNP, serum CRP and creatinine
levels, age, and body mass index
There was a significant positive correlation between the BNP and CRP levels in the cancer
patients (r = 0.360, p<0.01), but not in the non-cancer patients (Fig 3). In the non-cancer
patients, there was a significant positive correlation between the BNP and creatinine levels
(r = 0.261, p<0.01), but not in the cancer patients (Fig 4A). There also was a significant posi-
tive correlation between the BNP levels and age in the non-cancer patients (r = 0.340, p<0.01),
but not in the cancer patients (Fig 4B). There was no significant correlation between the BNP
levels and body mass index in either the patients with cancer or those without (Fig 4C).
Relationship between the plasma BNP and serum CRP levels in the
patients with hematological cancers versus solid tumors
Since paraproteinemia associated with hematological malignancies may influence the BNP lev-
els, we divided the cancer patients into those with hematological cancers (21 patients) and
those with solid tumors (59 patients). In the patients with hematological cancers, there was no
relationship between the BNP and CRP levels. In contrast, there was a significant positive rela-
tionship between the BNP and CRP levels in the patients with solid tumors (r = 0.486, p<0.01)
(Fig 5).
Multiple regression analysis of the BNP levels and potentially associated
factors
A multiple regression analysis was performed to identify the factors associated with increased
plasma BNP levels. In the patients with cancer, only the CRP concentration was associated
with the BNP levels independent of the age, creatinine level, hypertension, body mass index,
and the medication status (p<0.01) (Table 2). In the patients without cancer, the age and creat-
inine level were related to the BNP levels (Table 3).
Change in the plasma BNP levels before and after the surgery or
chemotherapy
In 28 cured patients with solid cancers who underwent a radical surgery, the plasma BNP levels
significantly decreased from 70.7±49.9 pg/ml to 45.0±29.7 pg/ml after the surgery (p<0.01)
Brain natriuretic peptide and cancer
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(Fig 6). On the other hand, in 7 relapsed or insufficiently treated patients with solid cancers,
the plasma BNP levels did not change after the surgery (from 98.8±80.7 pg/ml to 86.4±59.2 pg/
ml, p = 0.290). In 13 patients with hematological cancers who could be followed up after che-
motherapy, the plasma BNP levels did not change significantly after the chemotherapy (from
79.7±80.7 pg/ml to 47.7±40.7 pg/ml) (Fig 6). In addition, there was no significant relationship
between the BNP and CRP levels after the surgery or chemotherapy in each group (data not
shown).
Relationship between the plasma BNP and serum levels of the
inflammatory markers in mouse models of colon cancer
Compared with the control, mice with subcutaneous tumors with a size of approximated 10
mm induced by an injection of colon cancer cells (LIM 1215) had elevated plasma BNP levels
(591.1±374.5 vs. 206.2±122.7 pg/ml). In addition, the serum levels of the CRP, IL-6, and TNF-
α were significantly higher in the mice with colon cancer than in those without (CRP: 4.643
±1.369 vs. 3.340±0.498 μg/ml, p<0.05; IL-6: 10.8±8.8 vs. 2.6±1.5 pg/ml, p<0.05; TNF-α: 0.48
±0.15 vs. 0.28±0.06pg/ml, p<0.05), while the serum IL-1β did not change between the mice
with and without cancer. In addition, the plasma BNP level was correlated with the serum lev-
els of the CRP (r = 0.760, p<0.01), IL-6 (r = 0.600, p<0.05), and TNF-α (r = 0.625, p<0.05).
Discussion
To the best of our knowledge, the present study was the first to demonstrate that there was a
significant positive correlation between the plasma BNP and serum CRP levels in cancer
patients as well as cancer model mice without overt heart failure. This finding suggested that
the plasma BNP levels may have been elevated due to cancer-related inflammation in cancer
patients. Therefore, we should carefully differentiate elevated BNP levels in cancer patients due
to heart failure from cancer-related inflammation.
Elevated plasma BNP levels have been reported in patients with heart failure; BNP is used
as a biomarker for the diagnosis and guiding therapy in patients with heart failure [7].
Fig 1. Plasma brain natriuretic peptide (BNP) and serum C-reactive protein (CRP) levels in patients with and without cancer. Both the BNP and
CRP levels were significantly higher in the patients with cancer than in those without.
https://doi.org/10.1371/journal.pone.0178607.g001
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Therefore, in the present study, we excluded any patients with clinically evident heart failure
and cardiac disease requiring medical treatment or surgery in order to eliminate the influence
of heart failure on the BNP levels. In the present study, both the patients with and without can-
cer had a normal cardiac function. In addition to heart failure, the age, gender, obesity, hyper-
tension, and renal function have been shown to substantially influence the BNP concentration
[13–16]. In the present study, independent of possible associated factors, including the medi-
cation status, there were positive correlations between the BNP levels and the age or creatinine
levels, respectively, in the non-cancer patients; this observation was consistent with the results
of the previous studies. On the other hand, there were no significant correlations between the
BNP levels and the age or creatinine levels, respectively, in the cancer patients. These findings
might be due to the smaller number of cancer patients compared to non-cancer patients.
Alternatively, cancer itself or cancer-related inflammation might influence the creatinine
levels.
Fig 2. BNP levels in patients with different stages of cancer. Plasma BNP levels were significantly higher in cancer
patients with stage IV than in patients with stage I, II, and III. There were no significant difference in BNP levels between
cancer patients with stage I, II, and III. An ANOVA was used to assess the statistical significance followed by a Bonferroni
correction.
https://doi.org/10.1371/journal.pone.0178607.g002
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The plasma BNP levels were significantly higher in the patients with cancer than in those
without with similar characteristics such as the age, gender, body mass index, blood pressure,
renal function, and cardiac function as assessed by echocardiography. Furthermore, there was
a significant positive correlation between the BNP and CRP levels in the cancer patients,
which suggested that the plasma BNP levels may have been elevated due to cancer-related
inflammation. In addition, the plasma BNP levels are increased in an advanced stage of cancer
(stage IV), which might be accompanied by systemic inflammation. Furthermore, the plasma
BNP levels significantly decreased after a radical surgery in the patients with solid cancers, and
the plasma BNP levels tended to decrease after chemotherapy in the patients with hematologi-
cal cancers.
For the above reasons, we should carefully determine whether the higher BNP levels are
due to asymptomatic heart failure or the cancer itself in asymptomatic cancer patients. The
weak correlationship between the BNP and CRP levels in cancer patients in the present study
might suggest the inclusion of hidden heart failure. Although we excluded any patients with
evident heart failure by careful echocardiography in the present study, we could not deny all
possible heart failure because of the lack of any direct hemodynamic evidence. In addition, sar-
copenia or skeletal muscle loss is a common problem in cancer patients and can negatively
affect the physical function, which influences heart failure. In this kind of situation, an exercise
tolerance test might be useful to detect any hidden heart failure, because patients with heart
failure with a preserved ejection fraction display an impaired exercise capacity accompanied
with an inadequate hemodynamic response during exercise [17].
Inflammatory conditions are present before a malignant change occurs, and an oncogenic
change generates an inflammatory microenvironment that promotes the development of
tumors [11]. Numerous endogenous molecules involved in cancer-related inflammation have
been identified. These include transcription factors such as nuclear factor (NF)-κB and major
inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α
[18–21]. In particular, IL-6 is a key growth-promoting and anti-apoptotic inflammatory cyto-
kine. Activated NF-κB is an effector of IL-6, which promotes neoplasia [21–23]. In addition,
Fig 3. Relationship between BNP and CRP in patients with and without cancer. In non-cancer patients, there was no significant correlation between
BNP and CRP levels, but there was a significant positive correlation between BNP and CRP levels in cancer patients.
https://doi.org/10.1371/journal.pone.0178607.g003
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CRP is the prototypical short pentraxin. It is produced by the liver in response to IL-6 [24].
These findings suggest that, in the tumor microenvironment, inflammatory cells may produce
cytokines, particularly IL-6, as a response to tumor cells, tissue necrosis, and associated inflam-
mation. Furthermore, these cytokines may induce hepatocytes to synthesize CRP.
Fig 4. A. Relationship between the BNP and creatinine levels in the patients with and without cancer. In the non-cancer
patients, there was a significant correlation between the BNP and creatinine levels, but there was no correlation between
the BNP and creatinine levels in the cancer patients. B. Relationship between the BNP and age in the patients with and
without cancer. In the non-cancer patients, there was a significant correlation between the BNP level and age, but that
correlation was not observed in the cancer patients. C. Relationship between the BNP and body mass index in the
patients with and without cancer. There was no significant correlation between the BNP levels and body mass index in
either the patients with cancer or those without.
https://doi.org/10.1371/journal.pone.0178607.g004
Brain natriuretic peptide and cancer
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BNP has been shown to be upregulated at the transcriptional and translational levels by
pro-inflammatory cytokines in cardiac myocytes [12]. Pro-inflammatory signals are postulated
to stimulate members of the mitogen-activated protein kinase (MAPK) family and c-Jun
kinase, as well as other intracellular signaling cascades, which leads to the upregulation of the
BNP gene expression. TNF-α and IL-1β induce a significant increase in the BNP mRNA and
secretion via p38 MAPK in neonatal rat ventricular cardiomyocytes [25]. In addition, adminis-
tration of lipopolysaccharide to healthy men increases the plasma NT-pro BNP levels without
changing the heart rate or blood pressure [26]. In septic patients without systolic myocardial
dysfunction, the plasma BNP is correlated with the CRP and IL-1β [27]. Furthermore, the
plasma levels of NT-proBNP, CRP, and TNF-α in patients with rheumatoid arthritis (RA)
without clinical heart failure are higher than in control groups, suggesting that increases in the
NT-proBNP levels in RA patients are related to inflammation [28]. These findings support the
notion that elevations in the plasma BNP occur in association with inflammation, independent
Fig 5. Relationship between the BNP and CRP levels in the patients with hematological cancers versus solid tumors. In the patients with
hematological cancers, there was no relationship between the BNP and CRP levels. In contrast, there was a significant relationship between the BNP and
CRP levels in the patients with solid tumors.
https://doi.org/10.1371/journal.pone.0178607.g005
Table 2. Multiple regression analysis of the BNP levels and potential associated factors in patients with cancer.
Standard regression coefficient t statistic p value
CRP 0.361 3.088 0.003
Creatinine -0.041 -0.302 0.764
Age 0.155 1.244 0.216
Hypertension 0.007 0.031 0.476
Body mass index 0.078 0.644 0.522
ACEI/ARB -0.133 -0.673 0.503
β-blocker -0.050 -0.399 0.691
Calcium antagonist -0.012 -0.073 0.942
Diuretic 0.149 1.254 0.214
Statin -0.209 -1.874 0.065
https://doi.org/10.1371/journal.pone.0178607.t002
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of the cardiac function (Fig 7). This hypothesis was supported by our basic study showing that
animal models with subcutaneous tumors induced by an injection of colon cancer cells (LIM
1215) had an elevated plasma BNP level compared with the control and that the plasma BNP
level was correlated with the CRP, IL-6, and TNF-α serum levels.
In the present study, we also evaluated the correlation between the BNP and CRP levels in
the patients with hematological cancers and solid tumors. There was a significant positive rela-
tionship between the BNP and CRP levels in the patients with solid tumors, but not hemato-
logical cancers. The measurement of the BNP might have been affected by paraproteinemia
associated with hematological cancers. This finding is in agreement with a previous study
showing that marked elevations in the BNP were more common in patients with solid tumors
than hematologic malignancies [29]. This previous study also found no signs of a volume
Table 3. Multiple regression analysis of the BNP levels and potential associated factors in patients without cancer.
Standard regression coefficient t statistic p value
CRP 0.066 0.831 0.408
Creatinine 0.173 2.151 0.033
Age 0.246 2.957 0.004
Hypertension -0.021 -0.141 0.888
Body mass index -0.016 -0.201 0.841
ACEI/ARB 0.104 0.903 0.368
β-blocker 0.086 0.929 0.354
Calcium antagonist 0.076 0.740 0.461
Diuretic 0.090 1.123 0.263
Statin 0.005 0.060 0.952
CRP: C-reactive protein.
https://doi.org/10.1371/journal.pone.0178607.t003
Fig 6. In 28 cured patients with solid cancers who underwent a radical surgery, the plasma BNP levels significantly decreased after the surgery
(left panel, closed circles) (*p<0.01 vs the value before surgery). On the other hand, in 7 relapsed or insufficiently treated patients with solid cancers,
the plasma BNP levels did not change after the surgery (left panel, open circles). In 13 patients with hematological cancers, the plasma BNP levels tended
to decrease after the chemotherapy, but it did not reach a statistical significance.
https://doi.org/10.1371/journal.pone.0178607.g006
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overload in more than 70% of cancer patients with a markedly elevated BNP. On the other
hand, another report showed that patients with hematologic malignancies may have higher
than expected NT-proBNP values in response to hypervolemic states, which may be related to
a possible infiltration of the myocardium by substances produced in the setting of hematologi-
cal cancers [30]. Further study is needed to clarify the effects of paraproteinemia on the BNP
measurements.
The cardiac natriuretic peptides, particularly ANP, have been reported to inhibit the growth
of cancers in vitro and in vivo [8,9]. The effects of cardiac natriuretic peptides on cancer may
be mediated by intracellular messenger cyclic GMP formed by higher guanylate cyclase activ-
ity, which is part of the natriuretic peptide receptor-A complex. Cyclic GMP has been shown
to have a strong anticancer effect, reducing human pancreatic cancer cell volume in vivo [9].
Natriuretic peptide receptor-A knockout mice do not express growth of implanted cancer cells
[31]. Furthermore, a recent study has shown that ANP inhibits the adhesion of cancer cells to
atrial and vascular endothelial cells by suppressing the E-selectin expression that is promoted
by inflammation [32]. However, the present study was not designed to determine whether
endogenously elevated plasma BNP levels have anticancer or antimetastatic effects in cancer
patients.
Fig 7. Hypothesized relationship between cancer and the BNP level. In the tumor microenvironment, inflammatory cells, including macrophages,
produce various cytokines in response to tumor cells and tissue necrosis. In cardiomyocytes, BNP synthesis has been shown to be upregulated at the
transcriptional level by inflammatory cytokines. Based on these previous findings and our present study, we hypothesized that the production of BNP might
be increased in cancer patients by cancer-related inflammation independent of the cardiac function, renal function, and age.
https://doi.org/10.1371/journal.pone.0178607.g007
Brain natriuretic peptide and cancer
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To the best of our knowledge, there have been no previous reports showing that cancer cells
generate BNP. Therefore, we think that an elevated plasma BNP level reflects the elevated pro-
duction from cardiomyocytes in association with inflammation in cancer patients. However, a
few studies reported an ectopic production of ANP mRNA in small cell lung cancer specimens
from patients with this cancer [33,34]. Therefore, further studies are needed to evaluate the
possible production of BNP from cancer itself.
Some limitations of the present study need to be acknowledged. First, although we showed
the observational relationship between the BNP level and inflammation in cancer patients, the
direct causative proof of the exact role of inflammation in increased BNP levels in patients
with cancer is yet to be determined. Therefore, well-designed prospective studies to evaluate
the relationship between the plasma BNP levels and cancer-related inflammation are needed
in the future. Second, we could not confirm the absence of early-stage cancer by a systemic
screening procedure in all “patients without cancer”. Instead, in the present study, we con-
firmed significantly decreased BNP levels after a radical surgery in solid-cancer patients who
had undergone systemic screening examinations for other cancers and metastases. Further
studies are needed to clarify the relationship between the BNP and CRP levels in “ab initio”-
non-cancer patients validated by the systemic screening tests. Third, due to the small number
and heterogeneity of the cancer patients, we could not evaluate the effect of the various origins
or different stages of cancer on the results. Fourth, we could not provide an exact co-morbidity
index, which could be a major contributor to the elevated inflammation, for all patients
because of the unavailability of data due to the retrospective study design.
In conclusion, the plasma BNP levels were elevated in patients with cancer, probably due to
cancer-related inflammation. This result suggested that we need to consider the effect of can-
cer on the BNP levels when we use the BNP as an indicator of heart failure in cancer patients.
In other words, asymptomatic cancer patients with higher BNP levels should be diagnosed
whether the elevated BNP is due to asymptomatic heart failure or cancer. Further studies to
confirm these findings are needed.
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